Looking More Closely at Breast Cancer in Male Patients
Although breast cancer has historically been associated with female patients, the rates of men with breast cancer have been increasing over the past decade.
T-Cell Engagers Take Center Stage in Large B-Cell Lymphoma
Bispecific antibodies that engage T cells are an effective treatment modality in relapsed/refractory disease and are an important new treatment for relapsed large B-cell lymphoma.
Navigating Difficult Conversations in Cancer Pain Management
Difficult conversations in cancer pain management should include core values and principles, setting realistic expectations, and building the patient-client relationship from the very beginning.
Empower Your Clinical Staff to Meet the Growing Patient Volume
Oncology practices can create more access to care by leveraging the use of APPs, empowering nurses to practice at the top of their licensure, utilizing nurse navigators, and planning ahead.
Oral SERDs: Shifting the Outpatient Landscape of Metastatic Breast Cancer?
With a new approval for elacestrant, patients with ER+/HER2–, ESR1-mutated metastatic breast cancer have an oral alternative to fulvestrant.
Immune Engager Therapies Improve Responses, PFS in RRMM After CAR T-Cell Therapy
Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory CLL/SLL
Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment
Ruxolitinib Plus Belumosudil Confers a 55% Response Rate in GVHD
2 Commerce Drive Cranbury, NJ 08512